Health Condition 1: C61- Malignant neoplasm of prostate
Conditions
Interventions
Intervention1: MRI guided focal boost radiotherapy: New standard of care treatment in the form of:
Moderate hypofractionated RT,
Will receive a total dose of 62 Gy in 20 fractions to the entire prosta
Sponsors
Tata Medical Center
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age: above 18 years. 2. Participants must be histologically proven adenocarcinoma prostate 3. High-risk localized prostate cancer as per NCCN risk criteria cT3/T4 or Gleason 8-10 or PSA more than 20 ng/ml or Prostate cancer with metastases confined to pelvic lymph nodes cN1 on mpMRI and PSMA PET-CT scan 4. No contraindications for long-term hormone therapy or orchidectomy 5. Karnofsky Performance Score above 70
Exclusion criteria
Exclusion criteria: 1. Patients in whom a pelvic MRI is contraindicated. 2. Prior history of radiotherapy to the pelvis or prostatectomy. 3. Severe urinary symptoms or a high IPSS score more than 15 which in the opinion of the physician, precludes RT 4. Patients with known obstructive symptoms with stricture. 5. Any contraindication to radiotherapy, such as severe inflammatory bowel disease. 6. Unable to report for regular follow up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Freedom from Biochemical FailureTimepoint: 5 years | — |
Secondary
| Measure | Time frame |
|---|---|
| Acute genitourinary and gastrointestinal toxicityTimepoint: 3 months;Late genitourinary and gastrointestinal toxicityTimepoint: 2 years and 5 years;Metastasis free survivalTimepoint: 3 years and 5 years;Prostate cancer specific survivalTimepoint: 5 years;Overall survivalTimepoint: 5 years | — |
Countries
India
Contacts
Public ContactIndranil Mallick
Tata Medical Center, Kolkata
Outcome results
None listed